Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial

Details 詳細情報について

• CRID

  1360861711936562944

• DOI

  10.1016/s2352-3026(20)30354-9

• ISSN

  23523026

• Web Site

  https://api.elsevier.com/content/article/PII:S2352302620303549?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S2352302620303549?httpAccept=text/plain

• Data Source

  • Crossref